FDA Greenlights Empaveli for Two Rare Kidney Disorders Causing Kidney Failure

the U.S. Food and Drug Administration (FDA) authorized Empaveli (pegcetacoplan) injection for the treatment of C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in adults and children aged 12 and older. These rare kidney diseases, which often lead to kidney failure, now have their first approved treatment for pediatric C3G cases and for both adults and children with primary IC-MPGN.

C3G and IC-MPGN stem from an overactive complement system, a component of the immune system, which triggers immune deposits in the kidneys’ glomeruli—the structures responsible for filtering waste and excess fluids. This buildup causes inflammation and kidney damage. About half of those diagnosed progress to kidney failure within 5-10 years, often requiring dialysis or a kidney transplant. Over 50% of transplant recipients face disease recurrence in the new kidney, frequently resulting in transplant loss.

Empaveli, administered twice weekly through subcutaneous infusion, targets and suppresses part of the complement system to curb this damage. Its effectiveness was shown in a 26-week, randomized, double-blind, placebo-controlled study involving 124 patients aged 12 and older with C3G or primary IC-MPGN, including those with recurrent C3G after transplantation (but not those with prior transplants for IC-MPGN). Patients receiving Empaveli saw a 68% reduction in proteinuria (excess protein in urine, a sign of kidney damage) compared to the placebo group. The treatment also slowed the decline in kidney function over the study period.

Empaveli is contraindicated for patients with hypersensitivity to pegcetacoplan or its excipients and those with unresolved serious infections caused by encapsulated bacteria, which can lead to severe, life-threatening infections. Patients must receive or update vaccinations for these bacteria at least two weeks before starting treatment, unless delaying therapy poses greater risks. Due to these infection risks, Empaveli is distributed under a Risk Evaluation and Mitigation Strategy (REMS) program, requiring close monitoring for infection signs and immediate evaluation if suspected. Common side effects include infusion site reactions, fever, common cold symptoms (nasopharyngitis), flu, cough, and nausea.

This approval offers new hope for managing these rare, life-altering kidney conditions. For further details, check the FDA website or the Pharma Courses article. Let me know if you’d like more insights into the trial or Empaveli’s mechanism!